A changing haemophilia world: Opportunities and challenges for the Haemophilia journal.

This is a fascinating time for haemophilia and other congenital bleeding diseases, as recently reflected by major therapeutic innovations, such as the newly developed longer‐acting clotting factor concentrates, promising so‐called disruptive therapies, along with the lately reported successes of gene therapy trials in both haemophilia A and haemophilia B. These therapeutic innovations will likely and significantly impact the management and care of persons with haemophilia or other inherited bleeding diseases around the world. [...